| Development and validation of determinative and confirmatory LC-MS/MSmethodologies for total florfenicol and tulathromycin residues in bovine, equine and porcine kidney, liver and muscle tissues. | J Chromatogr B Analyt Technol Biomed Life Sci | 2015 Mar 1 | 25612770 |
| Clinical evidence for individual animal therapy for papillomatous digitaldermatitis (hairy heel wart) and infectious bovine pododermatitis (foot rot). | Vet Clin North Am Food Anim Pract | 2015 Mar | 25705026 |
| Antimicrobial susceptibility of Histophilus somni isolated from clinicallyaffected cattle in Australia. | Vet J | 2015 Feb | 25592262 |
| Pharmacokinetics of tulathromycin in edible tissues of healthy and experimentallyinfected pigs with Actinobacillus pleuropneumoniae. | Food Addit Contam Part A Chem Anal Control Expo Risk Assess | 2015 | 26247868 |
| Use of a proposed antimicrobial susceptibility testing method for Haemophilusparasuis. | Vet Microbiol | 2014 Aug 27 | 24984947 |
| Pharmacokinetics of tulathromycin in plasma and milk samples after a singlesubcutaneous injection in lactating goats (Capra hircus). | J Vet Pharmacol Ther | 2014 Apr | 23889045 |
| Impact of health management, health treatments, and zilpaterol hydrochloridesupplementation on carcass quality, color, and palatability traits in heifers. | J Anim Sci | 2013 Jul | 23658348 |
| Estimating tulathromycin withdrawal time in pigs using a physiologically basedpharmacokinetics model. | Food Addit Contam Part A Chem Anal Control Expo Risk Assess | 2013 | 23767965 |
| Pharmacokinetics and tissue elimination of tulathromycin following subcutaneousadministration in meat goats. | Am J Vet Res | 2012 Oct | 23013191 |
| Pharmacokinetics of tulathromycin and its metabolite in swine administered withan intravenous bolus injection and a single gavage. | J Vet Pharmacol Ther | 2012 Jun | 21749408 |